Alirocumab reduces MIs

Friday, April 12, 2019

This week in clinical cardiology:

  1. Alirocumab reduces both type 1 and 2 MIs.
  2. Despite failed primary endpoint, MI alert device has predictive value.
  3. Look for alcohol septal ablation in the next HOCM guideline.
  4. FDA: Forty ARBs free of nitrosamines.

You can contact the Cardiocast with ideas, suggestions, stories, or questions for Dr. Dwyer by emailing us at podcasts@mdedge.com and you can follow MDedge Cardiology on Twitter at @MDedgeCardio.

How to Listen

Podcast Participants

Jim Dwyer, MD
Jim Dwyer MD, FACC, FSCAI, is a cardiologist and avid horseman in Prescott, Ariz. Trained at Saint Louis University, he spent more than 30 years in interventional cardiology. He recently hung up his lead apron and has joined a private cardiology practice. Dr. Dwyer has been producing health segments for radio broadcast for 20 years. He has no disclosures.



More Episodes from Cardiocast (ARCHIVE)

View All Episodes